Should dapagliflozin (Farxiga) be held in a patient who is vomiting?

Hold Farxiga (Dapagliflozin) During Vomiting

Yes, Farxiga should be held immediately in a patient who is vomiting. This is a critical sick day medication rule to prevent life-threatening complications, particularly euglycemic diabetic ketoacidosis (DKA) and volume depletion.

Why This Matters

Vomiting creates a perfect storm of risk factors when combined with SGLT2 inhibitors like Farxiga:

• Volume depletion from fluid losses compounds the diuretic effect of dapagliflozin, increasing risk of hypotension, acute kidney injury, and hospitalization 1
• Ketoacidosis risk escalates dramatically because vomiting represents reduced caloric intake and metabolic stress—both precipitating factors for the potentially fatal complication of euglycemic DKA where blood glucose may be normal or only mildly elevated (<250 mg/dL) 1
• Persistent drug effect continues for 3+ days after stopping (with reports up to 2 weeks), meaning the window for harm extends beyond symptom resolution 1

The Evidence-Based Algorithm

Immediate action when vomiting occurs:

1. Stop Farxiga immediately 2, 3

2. Assess severity:

   • Mild vomiting (1-2 episodes/12 hours): Hold medication, monitor closely
   • Moderate (3-5 episodes/12 hours): Hold medication, ensure adequate fluid replacement
   • Severe (>4 episodes/12 hours OR inability to keep fluids down): Hold medication AND contact healthcare provider immediately 3

3. Implement "STOP DKA" protocol 2:

   • Stop SGLT2 inhibitor
   • Test for ketones (blood or urine)
   • Maintain fluid and carbohydrate intake if possible
   • Continue insulin (if applicable) at reduced doses

4. Monitor for ketoacidosis signs regardless of blood glucose level 1:

   • Nausea, abdominal pain, generalized malaise
   • Shortness of breath
   • Severe metabolic acidosis symptoms

When to Restart

Do NOT restart Farxiga until ALL of the following are met 1:

• Patient is clinically stable
• Oral intake has resumed and is adequate
• Vomiting has completely resolved
• No signs of ketoacidosis (if tested)
• Typically wait at least 72 hours after symptom resolution 3

The FDA label explicitly states to "withhold FARXIGA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis" and "resume FARXIGA when the patient is clinically stable and has resumed oral intake" 1.

Critical Pitfalls to Avoid

Don't be fooled by normal glucose levels. The most dangerous aspect of SGLT2 inhibitor-associated DKA is that it presents as "euglycemic" ketoacidosis—patients can have life-threatening ketoacidosis with blood glucose <200 mg/dL or even normal levels 4, 1, 5. This delays diagnosis and treatment in emergency settings.

Don't restart too early. The guideline consensus is clear: symptoms must be completely resolved AND the patient must have resumed adequate oral intake before restarting 2, 3. Premature restart risks recurrent decompensation.

Don't forget patient education. Patients must understand this is a temporary hold during acute illness, not permanent discontinuation of a medication providing significant cardiovascular and renal protection 2.

The Broader Context

This sick day guidance applies to all acute illnesses causing volume depletion—not just vomiting but also diarrhea, reduced fluid intake, fever, or any condition causing significant fluid losses 2, 3. The 2025 KDOQI guidelines specifically list "nausea, vomiting, diarrhea" as triggers to hold SGLT2 inhibitors during acute illness 2.

While Farxiga provides substantial benefits for heart failure, chronic kidney disease, and cardiovascular risk reduction 2, 6, 2, these benefits require the patient to be in a stable clinical state. During acute illness with vomiting, the risk-benefit ratio shifts dramatically toward harm, making temporary discontinuation the only appropriate action.